{"filing":{"accession_number":"0001493152-26-041716","cik":"0001828673","ticker":"HCWB","company_name":"HCW Biologics Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-04","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226041716/form8-k.htm"},"events":[{"id":31860,"run_id":29258,"accession_number":"0001493152-26-041716","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"HCW Biologics announced entry into an Exclusive Distribution Agreement with Akron Biotech for commercialization of HCW11-006 as a reagent for CAR-T cell manufacturing. This is a material strategic partnership and commercial milestone for a clinical-stage biopharmaceutical company, involving pre-payment commitments and distribution through an established network. While not a traditional M\u0026A transaction, it represents a significant operational and commercial development that would affect a reasonable investor's assessment of the company's commercialization strategy and revenue prospects.","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34883,"accession_number":"0001493152-26-041716","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"HCW Biologics announced entry into an Exclusive Distribution Agreement with Akron Biotech for commercialization of HCW11-006 as a reagent for CAR-T cell manufacturing. This is a material strategic partnership and commercial milestone for a clinical-stage biopharmaceutical company, involving pre-payment commitments and distribution through an established network. While not a traditional M\u0026A transaction, it represents a significant operational and commercial development that would affect a reasonable investor's assessment of the company's commercialization strategy and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:01:48.138940+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34883,"accession_number":"0001493152-26-041716","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"HCW Biologics announced entry into an Exclusive Distribution Agreement with Akron Biotech for commercialization of HCW11-006 as a reagent for CAR-T cell manufacturing. This is a material strategic partnership and commercial milestone for a clinical-stage biopharmaceutical company, involving pre-payment commitments and distribution through an established network. While not a traditional M\u0026A transaction, it represents a significant operational and commercial development that would affect a reasonable investor's assessment of the company's commercialization strategy and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:01:48.138940+00:00","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-09-08"}]}